SMMT Summit Therapeutics PLC
Company Analysis
Latest News
🔴 Summit Therapeutics is trading 4.23% down today with no clear company-specific catalyst
Summit Therapeutics is trading 4.23% down at $16.41 on October 13, 2026, with no clear company-specific announcement explaining the decline in available search...
🔴 Summit Therapeutics is trading 4.5% down today alongside declines in major indexes
Summit Therapeutics is trading at $17.14, down 4.51%, amid broader market weakness; the exact cause of the decline is not established. - No new...
🟢 Summit Therapeutics is trading 5% up today
Summit Therapeutics is trading 4.82% higher at $18.14 on October 7, 2026, with no clear company-specific reason for the intraday gain identified in available...
🔴 Summit Therapeutics is trading 4.2% down today amid a 2.50% XBI decline
Summit Therapeutics is trading 4.2% lower at $16.55 amid biotech-sector pressure, with the XBI down 2.50% during the session. - No new company-specific...
🟢 Summit Therapeutics is trading 4.03% up today after AstraZeneca completed its $2 billion equity investment
Summit Therapeutics is trading 4.03% up at $17.43 on October 5, 2026, after announcing AstraZeneca completed its $2 billion equity investment; the announcement...
Summit Teams With AstraZeneca, Daiichi Sankyo on Phase III Breast Cancer Trial
Summit Therapeutics has signed a clinical trial collaboration agreement with AstraZeneca and Daiichi Sankyo to evaluate its investigational drug ivonescimab...
🟢 Summit Therapeutics is trading 4.5% up today after AstraZeneca’s $2 billion investment
Summit Therapeutics is trading at $17.13, up 4.51% on September 30, 2026, following AstraZeneca’s $2 billion equity investment and collaboration on cancer-drug...
🟢 Summit Therapeutics is trading 13.4% up today after AstraZeneca’s $2 billion investment
Summit Therapeutics is trading 13.44% higher at $17.56 after AstraZeneca agreed to invest $2 billion and collaborate on cancer-treatment trials. - The...
Summit Therapeutics Announces $2.0 Billion Strategic Equity Investment from AstraZeneca
Summit Therapeutics entered into a securities purchase agreement with AstraZeneca Holdings B.V. for a private placement expected to generate $2.0 billion in...
AstraZeneca Bets $2 Billion on Summit Therapeutics — But Can a Pre-Revenue Biotech Justify a $17 Billion Valuation?
Shares of Summit Therapeutics surged 22.6% to $18.98 after AstraZeneca announced a $2 billion convertible preferred-share investment and clinical...
🟢 Summit Therapeutics is trading 22.6% up in pre-market after AstraZeneca announced a $2 billion strategic investment
Summit Therapeutics is trading 22.61% higher at $18.98 in pre-market after AstraZeneca’s $2 billion investment announcement. - The preferred shares convert at...
AstraZeneca Invests $2 Billion in Summit to Advance Cancer Drug
AstraZeneca will invest $2 billion in Summit Therapeutics through convertible preferred shares. The shares will convert at $18.36 per common share, a premium...
🟢 Summit Therapeutics is trading 16.3% up in after-hours trading with no confirmed new catalyst
Summit Therapeutics is trading 16.3% higher after hours at $18.00, with no new company announcement after the close confirmed in sources reviewed. - This...
🔴 Summit Therapeutics is trading 4.4% down; no clear company-specific catalyst identified
Summit Therapeutics is trading at $15.66, down 4.40%, with no clear company-specific catalyst identified for the September 25 decline. - The company’s latest...
🔴 Summit Therapeutics is trading 4.2% down today with no clear company-specific catalyst
Summit Therapeutics is trading 4.2% lower at $16.40, with no clear company-specific catalyst for the September 23, 2026 decline. - Reports of potential...
🔴 Summit Therapeutics is trading 5% down today amid an unexplained company-specific selloff
Summit Therapeutics is trading 5.32% down at $16.90, despite broad U.S. market gains on September 21, 2026, with no confirmed company-specific catalyst for the...
🔴 Summit Therapeutics is trading 5% down today with no confirmed catalyst
Summit Therapeutics is trading 5% down at $16.95 on September 21, 2026, with no company-specific announcement identified to explain the decline. - Broader...
🔴 Summit Therapeutics is trading 5.3% down today
Summit Therapeutics is trading 5.3% down at $16.92 on September 21, 2026, with no new company-specific announcement identified explaining the decline. - The...
🟢 Summit Therapeutics is trading 4.71% up in pre-market after major U.S. indexes rose overnight
Summit Therapeutics is trading at $18.69, up +4.71%, after a firm overnight market backdrop lifted major U.S. indexes. • The S&P 500 rose 0.69% and Nasdaq...
🟢 Summit Therapeutics rises 4.2% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...